

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035544 A1

(51) International Patent Classification⁷: **C07F 15/00** TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/CZ2004/000068

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 14 October 2004 (14.10.2004)

(25) Filing Language: Czech

(26) Publication Language: English

(30) Priority Data:
PV 2855-03 17 October 2003 (17.10.2003) CZ

(71) Applicant (*for all designated States except US*): PLIVA-Lachema a.s. [CZ/CZ]; Karasek 1, 621 33 Brno (CZ).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ZAK, Frantisek [CZ/CZ]; Rerychova 4, 635 00 Brno (CZ). CZA-JKA-POULOVÁ, Anna [CZ/CZ]; Lucni 2, 664 91 Ivancice (CZ).

(74) Agent: KUBAT, Jan; Traplova Hakr Kubat, Law and Patent Offices, Po Box 38, Pristavni 24, 170 00 Praha 7 (CZ).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*
- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/035544 A1
(54) Title: OXALIPLATIN WITH A LOW CONTENT OF ACCOMPANYING IMPURITIES AND A METHOD FOR PREPARATION THEREOF

(57) Abstract: Oxaliplatin with a low content of accompanying impurities originating from its preparation which contains, by weight, at most 0.01 %, preferably less than 0.001 %, of alkali metals, at most 0.0005 %, preferably less than 0.0002 %, of silver, and at most 0.01 %, preferably less than 0.001 %, of nitrates. A method for preparation of the said oxaliplatin resides in that a suspension of (SP-4-2)-dichloro-[(1R,2R)-1,2-cyclohexanediamine-N,N']platinum (II) in water is treated with silver nitrate, then, after removal of the solid phase, the obtained solution is treated with quaternary ammonium iodide of the formula (R)4NI, the separated solid phase is removed and the obtained solution is treated with oxalic acid, and the separated oxaliplatin is isolated, washed with water and a polar organic solvent or their mixture, dried, recrystallised from water, washed with water and polar organic solvent or their mixture, and dried.